 PHILADELPHIA, Oct. 06, 2022 GLOBE NEWSWIRE -- Cabaletta Bio, Inc. Nasdaq: CABA, a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present clinical and translational data from the DesCAARTesTM trial of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris mPV in a poster presentation at the upcoming 29th Annual Congress of the European Society of Gene Cell Therapy ESGCT, which is being held at the Edinburgh International Conference Centre in Edinburgh, Scotland from October 11-14, 2022. 